XSNX — NovAccess Global Share Price
0.000.00%
Last trade - 00:00- $0.37m
- $2.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 25th, 1997
- Public Since
- May 1st, 2002
- No. of Shareholders
- 354
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 44,602,725
- Address
- 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS, 44023
- Web
- https://novaccessglobal.com/
- Phone
- +1 2136429268
- Contact
- Jordan Darrow
- Auditors
- M&K CPAS, PLLC
Upcoming Events for XSNX
Similar to XSNX
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the NovAccess Global share price?
As of Today at 22:24 UTC, shares in NovAccess Global are trading at $0.01. This share price information is delayed by 15 minutes.
How has the NovAccess Global share price performed this year?
Shares in NovAccess Global last closed at $0.01 and the price had moved by -92.48% over the past 365 days. In terms of relative price strength the NovAccess Global share price has underperformed the S&P500 Index by -93.69% over the past year.
What are the analyst and broker recommendations for NovAccess Global?
There is no consensus recommendation for this security.
What is the NovAccess Global dividend yield?
NovAccess Global does not currently pay a dividend.
Does NovAccess Global pay a dividend?
NovAccess Global does not currently pay a dividend.
When does NovAccess Global next pay dividends?
NovAccess Global does not currently pay a dividend.
How do I buy NovAccess Global shares?
To buy shares in NovAccess Global you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NovAccess Global?
As of the previous close price of $0.01, shares in NovAccess Global had a market capitalisation of $0.45m.
Where are NovAccess Global shares listed?
Here are the trading details for NovAccess Global:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: XSNX
What kind of share is NovAccess Global?
Based on an overall assessment of its quality, value and momentum NovAccess Global is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NovAccess Global share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the NovAccess Global share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NovAccess Global. Over the past six months, its share price has underperformed the S&P500 Index by -58.84%.
As of the last closing price of $0.01, shares in NovAccess Global were trading -73.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NovAccess Global PE Ratio?
The NovAccess Global PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NovAccess Global?
NovAccess Global's management team is headed by:
- Daniel Martin - CHM
- Dwain Moris - Irvin - CEO
- Neil Laird - CFO